Lutropin Alfa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Lutropin Alfa |
| DrugBank ID | DB00044 |
| Brand Names (EU) | Luveris |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.04% |
Approved Indication (EMA)
Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level <1.2 IU/l.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | postural orthostatic tachycardia syndrome | 97.04% | DL |
| 2 | peptic esophagitis | 97.02% | DL |
| 3 | trichotillomania | 96.31% | DL |
| 4 | Raynaud disease | 95.65% | DL |
| 5 | duodenal ulcer (disease) | 95.58% | DL |
| 6 | Tourette syndrome | 95.18% | DL |
| 7 | esophageal disease | 94.93% | DL |
| 8 | sinoatrial block | 94.91% | DL |
| 9 | multiple endocrine neoplasia | 94.87% | DL |
| 10 | duodenogastric reflux | 94.58% | DL |
| 11 | duodenal obstruction | 94.44% | DL |
| 12 | sinoatrial node disease | 94.20% | DL |
| 13 | non-syndromic esophageal malformation | 93.46% | DL |
| 14 | amenorrhea (disease) | 93.07% | DL |
| 15 | active peptic ulcer disease | 92.75% | DL |
| 16 | esophageal ulcer | 92.70% | DL |
| 17 | progressive familial heart block | 92.58% | DL |
| 18 | adrenal gland hyperfunction | 92.42% | DL |
| 19 | gastrojejunal ulcer | 92.42% | DL |
| 20 | peptic ulcer perforation | 92.42% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.